# Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Source: https://onco.cc/trials/nct02802423/  
OnCo record `nct02802423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by BioLite, Inc., not yet recruiting.

## Summary

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. is a phase 1/2, interventional study registered as NCT02802423 by BioLite, Inc., with a registry enrolment figure of 44 participants, started 2027-01-01 and due to reach its primary completion in 2028-04-30. Interventions recorded: BLEX 404 Oral Liquid. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with histologically or pathologically diagnosed with advanced/metastatic triple negative (ER-, PR-, and HER2-negative) breast cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT02802423
- Phase: 1/2
- Setting: A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery
- Sponsor: BioLite, Inc.
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT02802423: https://clinicaltrials.gov/study/NCT02802423

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct02802423.json